Published in Hepatitis Weekly, November 27th, 2006
Study 1: A recent review published in the journal Current Opinion in Drug Discovery & Development discussed finger loop inhibitors of the hepatitis C virus (HCV) non-structural protein 5B (NS5B) polymerase.
"HCV infects millions of people worldwide and currently available therapies suffer from limited efficacy and severe side effects. This review describes the discovery of a novel class of non-nucleoside HCV NS5B polymerase inhibitors that inhibit the replication of viral RNA by binding to an allosteric site on the enzyme.
"Initial lead compounds...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.